Ozmosi | Dorocubicel Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Dorocubicel

Pronounced as: dor-oh-KYOO-bi-sel

Alternative Names: Dorocubicel, ECT-001, ECT001, ECT 001, um-171, um171, um 171
Clinical Status: Active
Latest Update: 2026-03-10
Latest Update Note: News Article

Product Description

UM171 patients benefit from rapid T cell reconstitution, which likely contributes to the absence of moderate/severe cGVHD, infection-related mortality, and late TRM observed in this cohort. Recently, results of a phase I/II trial revealed that single UM171-expanded CB transplant allowed the use of smaller CB units without compromising engraftment (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33022376/)

Mechanisms of Action: Cell Therapy, CD34

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ExCellThera inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dorocubicel

Countries in Clinic: Netherlands, United States

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Allogeneic Stem Cell Transplant|Graft vs Host Disease|Hematopoietic Stem Cell Transplant|Myelodysplastic Syndrome|Preleukemia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT04990323

ECT-001-CB.007

P2

Recruiting

Hematopoietic Stem Cell Transplant|Graft vs Host Disease

2026-06-01

2%

2024-02-21

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

2024-517583-36-01

ECT-001-CB.004

P2

Not yet recruiting

Allogeneic Stem Cell Transplant|Myelodysplastic Syndrome

2026-02-15

2025-05-02

Treatments

NCT04103879

ECT-001-CB.004

P2

Active, not recruiting

Myelodysplastic Syndrome|Preleukemia

2026-02-01

2%

2024-02-21

Primary Completion Date|Primary Endpoints